In August 2017, it was reported that Vida Ventures has participated in a $83.5 million Series B financing round for Homology Medicines.
In December 2017, it was announced that Vida Ventures participated in a $62 million Series B financing round for Pionyr Therapeutics.
In March 2018, Homology Medicines, one of the companies Vida Ventures has invested in, began trading on the Nasdaq Global Select Market under the ticker "FIXX". Homology Medicines has raised $165 million in its initial public offering.
In April 2018, it was announced that Vida Ventures participated in a $300 million Series A financing round for Allogene Therapeutics.
In May 2018, it was announced that Vida Ventures participated in a $18 million seed financing round for Kronos Bio.
In July 2018, it was announced that Vida Ventures participated in a $85.4 Series E financing round for Sutro Biopharma.
A genetic medicines company in Massachusetts that focuses on patients suffering from rare genetic diseases.
Kronos Bio is a Cambridge, Massachusetts-based therapeutics company working on research and development of therapies that modulate historically recalcitrant cancer targets.
Pionyr Immunotherapeutics is a San Francisco-based biotechnology company and developer of cancer immunotherapies designed to target the tumor microenvironment.
Associated investment funds
Karthik A Kulkarni